• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

Thumbnail
Date
2010-12-27
Author
Larsen, Christian P.
Grinyo, Josep
Medina-Pestana, Jose [UNIFESP]
Vanrenterghem, Yves
Vincenti, Flavio
Breshahan, Barbara
Campistol, Josep M.
Florman, Sander
del Carmen Rial, Maria
Kamar, Nassim
Block, Alan
Di Russo, Gregory
Lin, Chen-Sheng
Garg, Pushkal
Charpentier, Bernard
Type
Artigo
ISSN
0041-1337
Is part of
Transplantation
DOI
10.1097/TP.0b013e3181ff87cd
Metadata
Show full item record
Abstract
Background. At 1 year, belatacept was associated with similar patient/graft survival, better renal function, and an improved cardiovascular/metabolic risk profile versus cyclosporine A (CsA) in the Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial (BENEFIT) and Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT) studies. Acute rejection was more frequent with belatacept in BENEFIT. Posttransplant lymphoproliferative disorder (PTLD)-specifically central nervous system PTLD-was observed more frequently in belatacept-treated patients. This analysis assesses outcomes from BENEFIT and BENEFIT-EXT after 2 years of treatment.Methods. Patients received a more intensive (MI) or a less intensive (LI) regimen of belatacept or a CsA-based regimen.Results. Four hundred ninety-three of 666 patients(74%) in BENEFIT and 347 of 543(64%) in BENEFIT-EXT completed 2 years of treatment. the proportion of patients who survived with a functioning graft was similar across groups (BENEFIT: 94% MI, 95% LI, and 91% CsA; BENEFIT-EXT: 83% MI, 84% LI, and 83% CsA). Belatacept's renal benefits were sustained, as evidenced by a 16 to 17 mL/min (BENEFIT) and an 8 to 10 mL/min (BENEFIT-EXT) higher calculated glomerular filtration rate in the belatacept groups versus CsA. There were few new acute rejection episodes in either study between years 1 and 2. Because PTLD risk was highest in Epstein-Barr virus(EBV)(-) patients, an efficacy analysis of EBV(+) patients was performed and was consistent with the overall population results. There were two previously reported cases of PTLD in each study between years 1 and 2 in the belatacept groups. the overall balance of safety and efficacy favored the LI over the MI regimen.Conclusions. At 2 years, belatacept-based regimens sustained better renal function, similar patient/graft survival, and an improved cardiovascular/metabolic risk profile versus CsA; outcomes that were maintained in EBV (+) patients. No new safety signals emerged.
Citation
Transplantation. Philadelphia: Lippincott Williams & Wilkins, v. 90, n. 12, p. 1528-1535, 2010.
Keywords
Belatacept
Cyclosporine A
Kidney transplant
Survival
GFR
Sponsorship
Bristol-Myers Squibb
Genentech
Pfizer
Novartis
Astellas Pharma
Genzyme
Roche
URI
http://repositorio.unifesp.br/handle/11600/33174
Collections
  • EPM - Artigos [17701]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV